Krystal Biotech Inc (KRYS) — Cash Flow Quality Index
Krystal Biotech Inc (KRYS) has a Cash Flow Quality Index of 1.44x as of March 2026. Operating cash flow of $80.38 Million exceeds net income of $55.93 Million, indicating high earnings quality where cash backs reported profits. Explore KRYS cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Krystal Biotech Inc Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Krystal Biotech Inc across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check KRYS capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Krystal Biotech Inc (2023–2025)
Year-by-year earnings quality comparison for Krystal Biotech Inc. For live market cap and the full company financial profile, see Krystal Biotech Inc market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.98x | $200.87 Million | $204.83 Million | ▼ -29.2% |
| 2024 | 1.38x | $123.42 Million | $89.16 Million | ▲ +117.0% |
| 2023 | -8.12x | $-88.80 Million | $10.93 Million | — |